Oxford Nanopore Technologies (LON:ONT) Insider Acquires 70 Shares of Company Stock

Key Points

• Insider buying: Francis Van Parys acquired 70 Oxford Nanopore Technologies shares at GBX 215 each, investing £150.50. This follows purchases in August and September.
• Stock performance: Shares fell 1.1% to GBX 208.60, while remaining above their 50-day and 200-day moving averages. The company has a £2.04 billion market capitalization.
• Analyst outlook: Five analysts rate the stock Buy and one rates it Hold, producing a consensus “Moderate Buy” rating and a GBX 198.60 target price. Oxford Nanopore continues to report losses, including negative net margin and return on equity.

Oxford Nanopore Technologies plc (LON:ONT - Get Free Report) insider Francis Van Parys acquired 70 shares of the business's stock in a transaction dated Wednesday, October 14th. The shares were acquired at an average price of GBX 215 per share, for a total transaction of £150.50.

Francis Van Parys also recently made the following trade(s):

• On Monday, September 14th, Francis Van Parys acquired 96 shares of Oxford Nanopore Technologies stock. The stock was acquired at an average price of GBX 157 per share, with a total value of £150.72.
• On Wednesday, August 12th, Francis Van Parys bought 114 shares of Oxford Nanopore Technologies stock. The shares were acquired at an average cost of GBX 131 per share, with a total value of £149.34.

Oxford Nanopore Technologies Stock Down 1.1%

LON ONT traded down GBX 2.40 during trading hours on Wednesday, reaching GBX 208.60. 1,681,754 shares of the company's stock were exchanged, compared to its average volume of 9,552,693. The company's 50-day moving average is GBX 169.50 and its two-hundred day moving average is GBX 136.77. Oxford Nanopore Technologies plc has a one year low of GBX 95.61 and a one year high of GBX 238.80. The company has a debt-to-equity ratio of 9.86, a quick ratio of 6.01 and a current ratio of 3.52. The company has a market capitalization of £2.04 billion, a price-to-earnings ratio of -16.69 and a beta of 0.87.

Oxford Nanopore Technologies (LON:ONT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 19th. The company reported GBX (4.90) earnings per share for the quarter. Oxford Nanopore Technologies had a negative net margin of 54.66% and a negative return on equity of 35.45%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Citigroup cut shares of Oxford Nanopore Technologies to a "buy" rating in a research report on Monday, July 20th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a GBX 195 target price on shares of Oxford Nanopore Technologies in a report on Thursday, August 20th. Peel Hunt reissued a "hold" rating and issued a GBX 153 price target on shares of Oxford Nanopore Technologies in a research note on Monday, July 13th. JPMorgan Chase & Co. boosted their price target on Oxford Nanopore Technologies from GBX 190 to GBX 220 and gave the company an "overweight" rating in a report on Thursday, August 27th. Finally, Berenberg Bank reduced their price objective on Oxford Nanopore Technologies from GBX 220 to GBX 200 and set a "buy" rating for the company in a research report on Wednesday, August 19th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Oxford Nanopore Technologies currently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 198.60.

About Oxford Nanopore Technologies

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.